Completed PHASE4 INTERVENTIONAL 1-arm NCT00192140

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Sponsor: MedImmune LLC

Conditions Influenza

Interventions FluMist

Updated 7 times since 2017 Last updated: Dec 27, 2007 Started: Jun 30, 2004 Primary completion: Oct 31, 2004 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00192140, this PHASE4 trial focuses on Influenza and remains completed. Sponsored by MedImmune LLC, it has been updated 7 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bardstown, United States , Charlottesville, United States , Chicago, United States , Columbus, United States , Huntington, United States , Miami, United States , Nashville, United States , Omaha, United States , Pittsburgh, United States and 1 more location